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PROCESS OF PRODUCING EQUINE VIRAL 
ARTERITIS VACCINE AND PRODUCT THEREOF 
John T. Bryans, William H. McCollum, and James C. 
Wilson, Lexington, Ky., and Elvis R. Doll, deceased, 
late of Lexington, Ky., by Mable R. Doll, executrlx, 
Lexington, Ky., assignors to The University of Ken 
tucky Research Foundation, Lexington, Ky. 
No Drawing. Filed Oct. 14, 1968, Ser. No. 767,530 
Int. Cl. ClZk 9/00 
US. Cl. 424—89 4 Claims 
ABSTRACT OF THE DISCLOSURE 
A process is disclosed for producing an avirulent atten 
uated live virus vaccine for use in immunizing horses 
against equine viral arteritis and for simultaneously obvi 
ating the transmission of the disease from a vaccinated 
horse to a non-vaccinated horse. The invention also in 
cludes the product derived from practice of the process 
and typical examples of the e?’icacy of the product are 
disclosed. 
BACKGROUND OF THE INVENTION 
Based upon research of E. R. Doll, John T. Bryans, 
William H. McCollum and M. E. W. Crowe (Cornell 
Veterinarian 47: 3-41, 1957) a ?lterable agent causing 
arteritis of horses and abortion of mares and identi?able 
as the Bucyrus strain of equine viral arteritis was isolated. 
In addition, the work of William H. McCollum, E. R. Doll , 
and James C. Wilson reported in the American Journal of 
Veterinary Research, 23: 465-469, May 1961, deals not 
only with the Bucyrus strain, but also with the.Penn strain 
of the virus. Since speci?c lesions in the small arteries of 
horses infected fatally by the virus were noted, the term, 
equine viral arteritis, was chosen to distinguish the disease 
from other equine diseases. Characteristic symptoms of 
the thus identi?ed disease include fever, conjunctivitis, 
palpebral edema, congested and hemorrhagic nasal mu 
cosa, edema of the legs, respiratory dit?culty, colic, diar 
rhea, depression, muscular weakness and prostration. 
Moreover, and of especial commercial signi?cance in the 
breeding of race horses, the virus may cause severe losses 
from abortion. An abortion incidence rate of up to 80% is 
not unusual and a high mortality rate potential also is 
found. 
A further characteristic of the virus is that it is readily 
transmitted from one horse to another by various methods 
of contact, such as by nasopharyngeal secretions. Since 
conventional animal husbandry practices preferably do 
not employ the enforced isolation of animals from each 
other, the solution to the problem of immunizing against 
the disease must also solve the problem of transmission of 
the disease from an immunized animal to a non-immu 
nized animal. For example, in earlier work on the develop 
ment of a method for producing a live vaccine and as re 
ported by William H. McCollum, E. R. Doll, James C. 
Wilson and Catherine B. Johnson (American Journal of 
Veterinary Research 22: 731-735 July 1961) it was found 
that when horses were inoculated by intramuscular in 
jections with the Bucyrus strain of the virus passaged 46 
times through horse kidney cultures alone, the virulence 
of the disease was reduced, but that the virus was still re 
coverable from nasopharyngeal secretions of the inocu 
lated horse. 
As an additional consideration in preparing a live virus 
vaccine to solve the problems as indicated above, it was 
essential that such vaccine be incapable of transmitting 
other viruses such as those of infectious anemia or the 
factor causing acute liver atropy in horses. Accordingly, 
the present invention relates to an attenuated live virus 
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vaccine which does not contain any infectious agent path 
ogenic for horses except the virus per se. 
SUMMARY 
The vaccine of the invention is characterized by its 
ability to stimulate the production of anti-equine arteritis 
virus antibodies when introduced into non-immune horses 
and without producing the usual symptoms of infectious 
equine arteritis in these horses or the transmission of the 
disease to other horses in contact with the treated horses. 
The live virus contained in the vaccine has been attenu 
ated by having been grown in rabbit kidney cultures, pref 
erably by means of from 80 to 111 serial passages therein, 
after ?rst having been grown in about 131 serial passages 
in horse kidney cultures. 
Among the objects of the invention are the provision of 
an improved process for producing an equine viral arteri 
tis vaccine; a vaccine which may be administered to horses 
in a wide range of dosages; a yaccine which is adapatable 
to immunization of horses under a wide variety of hus 
bandry practices; a vaccine which is safe for use in horses 
in a wide range of dosages; a vaccine which is adaptatable 
order of immunity to horses for periods of one year or 
more; a vaccine which is substantially free of serious 
equine pathogens other than that of equine viral arteritis; 
and a vaccine which does not result in signi?cant hema 
tological disturbances or febrile reactions in the treated 
horse. 
‘ice 
DESCRIPTION ‘OF THE PREFERRED 
EMBODIMENTS 
The avirulent virus, or vaccine product, represented by 
the invention may be produced by employing certain pro 
cedures as outlined below and as indicated by the follow 
ing examples. - 
Example A 
Cell cultures were prepared from cortices of kidneys 
from horses of various ages according to the trypsin digest 
method of Youngner (Proc. Soc. Exptl. Brol. & Med. 85 
(1954): 202-205). The cells were grown at 37° C. in a 
medium containing 10% horse serum, 0.5% lactalbumin 
hydrosylate and either 89.5% Eagle’s medium or 89.5 % 
Earle’s solution. In Leigh-ton tubes, 1.2 ml. of 0.5% cell 
suspension was used; Whereas, in 32 oz. prescription 
bottles, 80.0 ml. was used. 
The medium was replaced on the 3rd day if cultures 
were not seeded with virus at that time. Otherwise, when 
the cultures were ready for use, the nutrient medium was 
removed, the cell monolayer was washed once or twice 
w1th. phosphate-buffered saline solution and the nutrient 
medium was replaced with a maintenance medium con 
s1st1ng of 2.0% calf serum, 0.5% lactalbumin hydrolysate 
and either 97.5% Eagle’s medium or 97.5% Earle’s 
solution. Penicillin (100 units (ml.) streptomycin (100 
mg./ml.)), and nystatin (10 units/ml.) were used in 
all mediums. 
The virus source was derived from the spleen of a 
fetus aborted by experimental infection with native 
Bucyrus strain of equine arteritis virus. Twenty percent 
suspenslons of splenic tissues were prepared by mechani 
cally chopping the tissue into ?ne pieces using phosphate 
butfered saline solution as diluent. The supernatant liquid 
,collected after centrifuging at 1,000 relative centrifugal 
force for ?ve minutes served as the inoculum for cell 
cultures. 
The equine kidney cultures as described and grown on 
cover slips contained in Leighton tubes were inoculated 
with supernatant ?uids prepared as described. These cul 
tures were examined microscopically each day. The ?uids 
were collected from these cultures after 5 or 6‘ days, and 
0.2 ml. volumes were passed to Leighton tubes containing 
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10-day old kidney cell cultures, and serving as the be 
ginning of the serial passages. 
One hundred thirty-one such serial passages in the 
horse kidney cultures were conducted in order to provide 
the basic inoculum of material with which the subsequent 
procedure as outlined in Example B was carried out. 
Example B 
Kidneys from healthy rabbits were dispersed according 
to the above trypsin digest method of Youngner. The cells 
were suspended in a growth medium consisting of 10% 
calf serum, 0.5% lactalbumin hydrolysate and 89.5% 
Eagle’s basic medium. Leighton tubes received 1.2 m1. of 
cell suspension and 4-ounce prescription bottles received 
15 ml. A complete replacement of growth medium was 
made after 3 or 4 days. When cell growth became ade 
quate for inoculation, the growth medium was removed 
and replaced with a maintenance medium consisting of 
2.0% calf serum, 0.5% lactalbumin hydrolysate and 
97.5% Eagle’s basic medium. 
Penicillin (100 units per ml.), streptomycin (100 mg. 
per ml.) and nystatin (10 units per ml.) were employed 
in all mediums and inoculations were at 37° C. 
Upon inoculating the rabbit kidney culture with the 
virus which had previously received 131 serial passages in 
horse kidney cultures according to Example A, the rabbit 
kidney culture was examined daily for 6 days at 100 
magni?cation for cytopathic evidence of infection char 
acteristic of arteritis virus activity. Fifty percent end 
points, expressed in terms of tissue culture infective doses 
(TCID) were calculated according to conventional meth 
ods. A serial passaging of the attenuated virus was then 
begun and was continued to a total of 32 such passages. 
In other preparations of the vaccine serial passages of 
50, 80, 90, 110 and 111 in the ribbit Ikidney cultures 
were employed. 
,VACCINATION PROCEDURES 
In employing the vaccine and in testing its results as 
indicated by the following tables, the immunizing viruses 
were injected into the cervical muscles of the horses. In 
general, the volume of the immunizing dose was 2 ml. 
and the dose of virus was adjusted to 104 to 105 TCID50 
by diluting in maintenance medium or trypticase broth. 
The rabbit kidney passage levels tested for tolerance by 
horses and for immunization were 32, 50, 80, 90, 110, 
and 111. After vaccination, the horses were observed 
twice daily for 10 to 16 days for signs of infection and 
for recording body temperatures, in some groups white 
blood cells and differential counts were made daily and 
in others, nasopharyngeal secretions were collected daily 
for virus recovery in tissue cultures. 
For challenge inoculations, the 'Bucyrus strain of virus 
was used in the form of a 10 ml. volume instilled in the 
nasopharnyx passage with a plastic catheter and compris 
ing a 20% suspension of infective spleen from control 
horses which died of uncomplicated arteritis, 5 to 7 days 
after being challenged. The virus titer of the challenge 
inoculums ranged from 104 to 107 TCID50/ml. 
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The e?icacy of the process of preparing the vaccine and 
of the product produced thereby will be apparent to 
those skilled in the art upon consideration of the follow 
ing tables indicating the results obtained from using the 
vaccine in the described vaccination procedures. 
TABLE I 
Immunization ofhorses with attenuated live equine viralarteritis vaccine 
Passage level Dose of Days from 
Number of of immuniz- virus vaccination Result of 
horses ing virus *\ TCIDso to challengeb challenge“ 
2X10 4 21 Immune 
2X10 2 24 Do. 
2X10 3 24 Do. 
2X10 4 24 D0. 
2X10 5 24 D0. 
2X10 5 28 Do. 
2X10“.7 21 Do. 
2X10 7 237 D0. 
2X10 7 94 Do. 
2X10“ 26 Do. 
B Number of passages in rabbit kidney cultures following 131 passages in 
horse kidney cultures. 
b Nasopharyngeal inoculation with 10 ml. of 20% suspension of spleen 
containing parent Bucyrus strain. 
1‘These tests included 32 unvaccinated control horses. All had acute 
attacks of arteritis following nasopharyngeal inoculation; 17 (53%) died. 
The results indicate that the vaccine appears to be uni 
formly active in establishing immunity and that it may 
be used at a diverse range of TCID50 doses. For example, 
as few as 102 TCID50 doses were adequate and as much 
as 10'’-5 TCIDSO doses were tolerated with the post vaccina 
tion reaction being comparable to that following doses 
below 105 TCID50. 
3 0 TABLE 11 
Duration of immunity followingh intramuscular vaccination of yearling 
orsesa 
Results of challenge inoculationc 
35 Time from Virus recovery on postinoculation 
Horse vaccination daysd challenge 
identity to challenge Clinical —— 
number (months) response 1 2 3 4 5 6 7 
1,087 ____ ._ 4 Immune- -__ — — — — -— — — 
1,083 ____ .. i ..___do ____ __ — —- — —- — — — 
1,09 ____ . _ _ -— — — - -— — — 
40 ,091 ____ __ 4 ..__.do ____ ._ - - - - - - - 
1,135b____- 0 Susceptible _ — -— — — - -~ - 
1,092 ____ ._ 8 une._-_ + + + + 0 0 0 
1,093 ____ _- 8 _--_-do ____ _- 0 0 0 0 0 0 0 
1,095 ____ __ 8 ___-_do ____ __ -l— 0 0 0 0 0 0 
1,164b____- 0 Susceptible _ + + + + + D — 
1,165b____- 0 .____do ____ .- + + + + D — - 
45 1,1e6b_____ 0 .-___do .... -_ + + + + + 0 0 
1,097 ____ __ 12 Immune___. + 0 0 0 0 0 0 
1,098 ____ __ 12 __-_-do ____ -_ 0 0 0 0 0 0 0 
,099 .... __ 12 ___._do___ _ 0 0 0 0 0 0 0 
1,100 ____ __ 12 ___--d0 ____ _. 0 0 0 0 0 0 0 
1,185b_____ 0 Susceptible - + + + + + + + 
,186b____- 0 _____do .... ._ + + + + + + D 
50 
55 
?Virus passaged 131 times in horse kidney and 80 times in rabbit kidney 
cultures. Dose was 2><104-7 TCIDW. 
b Control horses. 
vParent Bucyrus strain-10 ml. of 20% suspension of infective spleen 
instilled in nasopharynx. 
dBy inoculation of tissue cultures with nasopharyngeal secretions. 
NOTE.——=N0 test made; +=virus recovered; D=dead horse. 
The results thus indicate that a biological immunity 
was present in 2 of 3 horses challenged eight months after 
vaccination and in each of 4 horses challenged twelve 
months after vaccination. 
TABLE III 
Failure of transmission of virus from horses vaccinated intramuscularly to non-vaccinated 
horses kept in enforced close contact 
Number of Vaccinated horses Contact horses 
horses in 
testa Dose of TC. Results of Contact 
-— vaccine virus passage challenge period Results of challenge 
V C (TCIDao) levelc inoculationb (days) inocula 
6 5 5><107-5 RK 32 All immune... 28 All susceptible; 3 died. 
2 2 2x105 RH 80 ._-__do ______ ._ 21 All susceptible; 1 died. 
6 6 2X10° RK 80 _.-__do ______ __ 28 Do. 
7 7 5X106 HaK 30 _____do ______ __ 21 All susceptible; 4 died. 
lIVaccinated horses V and contact horses 0 were paired 1+1 in box stalls at the time of 
vaccination and kept in enforced contact for the period shown. 
blNative Bucyrus strain, 10 ml. of 20% suspension of infective spleen instilled into the 
nasopharynx. 
c RK=rabbit kidney. Viruses had been passaged 131 times in horse kidney followed by 32 
or 80 passages in rabbit kidney cultures. HaK=hamster kidney. Virus had been passaged 
83 times in horse kidney and 30 times in hamster kidney cultures. 
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During these tests each pair of horses was fed and 
watered from common containers and excreta was allowed 
to accumulate in the stalls. The results indicate that if 
the vaccine virus is excreted during the immediate post 
vaccination period, it is not excreted in su?icient quantity 
or in a state of virulence adequate for infecting and im 
munizing other horses kept in enforced close contact. 
In addition to the tests upon the vaccine product indi 
cated by Tables I, II, and III, other tests were made in 
cluding dual vaccinations of pregnant mares; thermal re 
ations of horses injected with the vaccine; and back-pas 
sage tests involving the taking of blood or plasma from 
inoculated horses and its injection into non-vaccinated 
horses to determine the efficacy of serial passages in the 
horse itself. Results indicate that the invention when thus 
utilized will not cause abortion of the fetus of the mare 
by the vaccine virus; that no signi?cant febrile reactions 
of horses injected with the vaccine can be expected; and 
that the back-passage of the vaccine virus through serial 
passage in horses will generally provide immunity through 
?ve of such back-passages. 
In view of the above disclosure, it will be noted that 
the several objectives of the invention are achieved and 
other advantageous results obtained. 
What is claimed is: 
1. The process of producing an attenuated vaccine for 
immunizing horses against equine viral arteritis which 
comprises introducing an inoculum of infectious equine 
virus into a tissue culture medium containing viable cells 
of horse kidney tissue, inoculating said tissue culture 
medium until multiplication of the virus has begun, there 
after separating an inoculum of said virus and serially 
passing the virus through horse kidney tissue cultures for 
at least about 131 passages, then serially passing the re 
sulting attenuated virus for at least about 30 passages 
through rabbit kidney tissue cultures to further attenuate 
the virus and to produce an elfective and safe live virus 
vaccine. 
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2. The process of producing an attenuated vaccine for 
immunizing horses against equine viral arteritis which 
comprises introducing an inoculum of infectious equine 
arteritis virus into a tissue culture medium containing 
viable cells of horse kidney tissue, inoculating said tissue 
culture medium until multiplication of the virus has begun, 
thereafter separating an inoculum of said virus and serial 
ly passing the virus through horse kidney tissue cultures 
for at least about 131 passages, and then serially passing 
the resulting attenuated virus through rabbit kidney tissue 
cultures for not less than about 32 passages and not more 
than about 111 passages to further attenuate the virus. 
3. An infectious equine viral arteritis virus containing 
a multiplicity of tissue culture infectious doses of virus 
per milliliter capable of stimulating the production of 
protective infectious equine arteritis antibodies when in 
tramuscularly injected into non-immune horses without 
producing the usual symptoms of infectious equine ar 
teritis, made by the process of claim 2. 
4. The product of claim 3 wherein the dose comprises 
an amount of virus ranging from about 20 to about 
2><107~5 TCID5O per milliliter. 
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